Drug Discovery

Neurocrine Biosciences, Jnana Therapeutics to discover medicines for CNS disorders

Neurocrine Biosciences and Jnana Therapeutics have entered into a research collaboration to discover novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders.

Inovio develops DNA-encoded monoclonal antibody checkpoint inhibitor

Inovio Pharmaceuticals said that it has completed animal testing of DNA-encoded monoclonal antibodies targeting the immune checkpoint molecule CTLA-4.

Sitryx launches with $30m funding to develop disease-modifying therapeutics

New biopharmaceutical company Sitryx has been launched with $30m fundraising for the development of disease modifying therapeutics in immunometabolism.

Arrowhead, Janssen sign $3.7bn license and collaboration deal

Biopharmaceutical firm Arrowhead Pharmaceuticals has signed a license and collaboration agreement with Janssen Pharmaceuticals for the development and commercialization of hepatitis B virus (HBV) treatment, ARO-HBV.

Boston Pharmaceuticals buys Novartis’ three anti-infective drug candidates

Boston Pharmaceuticals has signed a licensing and equity agreement with Novartis for the worldwide rights to three of the latter's anti-infective candidates for the potential treatment of Gram-negative infections.

Kite, HiFiBiO to develop technology for discovery of neoantigen-reactive TCRs to treat cancer

Gilead firm Kite and HiFiBiO Therapeutics have entered into a research collaboration and license agreement to develop technology for the discovery of neoantigen-reactive T cell receptors (TCRs) to treat various cancers such as solid tumors.

Kala Pharmaceuticals raises $110m financing to achieve significant milestones

Us biopharma company Kala Pharmaceuticals has closed a $110m credit facility with funds managed by healthcare focused investment firm Athyrium Capital Management.

Cancer startup GO Therapeutics signs $195m licensing deal with Roche

GO Therapeutics has signed a license agreement with Roche for new glycotargeting bispecific cancer treatment.

KSQ Therapeutics raises $80m financing to advance oncology drug candidates

KSQ Therapeutics has secured $80m series C financing to advance oncology drug candidates generated from its CRISPRomics drug discovery engine into clinical studies.